Epigenetics and Companion Diagnostics: Opportunities and Challenges
2023; Future Medicine; Volume: 15; Issue: 17 Linguagem: Inglês
10.2217/epi-2023-0203
ISSN1750-1911
AutoresDesislava K. Tsoneva, Manlio Vinciguerra,
Tópico(s)Molecular Biology Techniques and Applications
ResumoEpigenomicsVol. 15, No. 17 EditorialEpigenetics and companion diagnostics: opportunities and challengesDesislava K Tsoneva & Manlio VinciguerraDesislava K Tsoneva https://orcid.org/0000-0002-8141-2482Department of Medical Genetics, Medical University of Varna, 55 Marin Drinov str., Varna, BulgariaDepartment of Translational Stem Cell Biology, Research Institute of the Medical University, 55 Marin Drinov str., Varna, Bulgaria & Manlio Vinciguerra *Author for correspondence: E-mail Address: manlio.vinciguerra@mu-varna.bghttps://orcid.org/0000-0002-1768-3894Department of Translational Stem Cell Biology, Research Institute of the Medical University, 55 Marin Drinov str., Varna, BulgariaPublished Online:4 Sep 2023https://doi.org/10.2217/epi-2023-0203AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: companion diagnosticsepigeneticsnononcological diseasesoncological diseasesReferences1. Feinberg AP. The key role of epigenetics in human disease prevention and mitigation. N. Engl. J. Med. 378(14), 1323–1334 (2018).Crossref, Medline, CAS, Google Scholar2. Tordini F, Aldinucci M, Milanesi L, Liò P, Merelli I. The genome conformation as an integrator of multi-omic data: the example of damage spreading in cancer. Front. Genet. 7 (2016). http://journal.frontiersin.org/article/10.3389/fgene.2016.00194/fullMedline, Google Scholar3. Jørgensen JT. Companion and complementary diagnostics: clinical and regulatory perspectives. Trends Cancer 2(12), 706–712 (2016).Crossref, Medline, Google Scholar4. Tsoneva DK, Ivanov MN, Conev NV, Manev R, Stoyanov DS, Vinciguerra M. Circulating histones to detect and monitor the progression of cancer. Int. J. Mol. Sci. 24(2), 942 (2023).Crossref, Medline, CAS, Google Scholar5. Neel DS, Bivona TG. Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma. NPJ Precis. Oncol. 1(1), 3 (2017).Crossref, Medline, Google Scholar6. Lo YMD, Corbetta N, Chamberlain PF et al. Presence of fetal DNA in maternal plasma and serum. Lancet 350(9076), 485–487 (1997).Crossref, Medline, CAS, Google Scholar7. Allard WJ, Terstappen LWMM. CCR 20th anniversary commentary: paving the way for circulating tumor cells. Clin. Cancer Res. 21(13), 2883–2885 (2015).Crossref, Medline, Google Scholar8. Pantel K, Alix-Panabières C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol. Med. 16(9), 398–406 (2010).Crossref, Medline, Google Scholar9. Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164(1–2), 57–68 (2016).Crossref, Medline, CAS, Google Scholar10. Achour B, Gosselin P, Terrier J et al. Liquid biopsy for patient characterization in cardiovascular disease: verification against markers of cytochrome P450 and P‐glycoprotein activities. Clin. Pharm. Ther. 111(6), 1268–1277 (2022).Crossref, Medline, CAS, Google Scholar11. Benincasa G, Mansueto G, Napoli C. Fluid-based assays and precision medicine of cardiovascular diseases: the 'hope' for Pandora's box? J. Clin. Pathol. 72(12), 785–799 (2019).Crossref, Medline, CAS, Google Scholar12. Gaitsch H, Franklin RJM, Reich DS. Cell-free DNA-based liquid biopsies in neurology. Brain 146(5), 1758–1774 (2023).Crossref, Medline, Google Scholar13. Buzova D, Maugeri A, Liguori A et al. Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD). Clin. Epigenet. 12(1), 126 (2020).Crossref, Medline, CAS, Google Scholar14. Buzova D, Braghini MR, Bianco SD et al. Profiling of cell‐free DNA methylation and histone signatures in pediatric NAFLD: a pilot study. Hepatol. Commun. 6(12), 3311–3323 (2022).Crossref, Medline, CAS, Google Scholar15. US FDA. List of cleared or approved companion diagnostic devices (in vitro and imaging tools) (2023). www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-toolsGoogle Scholar16. Ltd Research and Markets. Companion diagnostics: technologies and markets (2023). www.researchandmarkets.com/reports/5416606/companion-diagnostics-technologies-and-marketsGoogle Scholar17. Ltd Research and Markets. Global aspirin market–forecasts from 2022 to 2027 (2022). www.researchandmarkets.com/reports/5649095/global-aspirin-market-forecasts-from-2022-toGoogle Scholar18. Maliepaard M, Nibi P, Nibi G, Pasmooij AMG. Evaluation of companion diagnostics in scientific advice and drug marketing authorization applications by the European Medicines Agency. Front. Med. 9, 893028 (2022).Crossref, Google Scholar19. Orellana García LP, Ehmann F, Hines PA, Ritzhaupt A, Brand A. Biomarker and companion diagnostics–a review of medicinal products approved by the European Medicines Agency. Front. Med. 8, 753187 (2021).Crossref, Google Scholar20. EMA. Guidance on the procedural aspects for the consultation to the European Medicines Agency by a notified body on companion diagnostics (2022). www.ema.europa.eu/en/documents/scientific-guideline/guidance-procedural-aspects-consultation-european-medicines-agency-notified-body-companion_en.pdf.Google Scholar21. Agarwal A, Snyder G, Ressler D. The current and future state of companion diagnostics. PGPM 8, 99–110 (2015).Crossref, Google Scholar22. Tanaka A, Suzuki H, Toyoshima S, Nagai N. Co-development of oncology drugs and companion diagnostics: analyses of approval lags and drug development periods in recently approved cases in Japan. Ther. Innov. Regul. Sci. 56(1), 85–95 (2022).Crossref, Medline, Google Scholar23. Fridlyand J, Simon RM, Walrath JC et al. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nat. Rev. Drug. Discov. 12(10), 743–755 (2013).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 15, No. 17 STAY CONNECTED Metrics Downloaded 5 times History Received 6 June 2023 Accepted 16 August 2023 Published online 4 September 2023 Published in print September 2023 Information© 2023 Future Medicine LtdKeywordscompanion diagnosticsepigeneticsnononcological diseasesoncological diseasesFinancial & competing interests disclosureThe authors are funded by the Ministry of Education and Science of Bulgaria under the National Scientific Programme "Excellent Research and People for the Development of European Science" 2021 (VIHREN) of the Bulgarian National Science Fund, contract #KP-06-DV/4 from 12/15/2021; by the Bulgarian National Science Fund, contract #KP-06-N53/6 from 11/11/2021. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)